As it fights loom­ing com­pe­ti­tion on Sub­ox­one, In­di­v­ior gets FDA OK on new schiz­o­phre­nia drug

British drug­mak­er In­di­v­ior got the green light from US reg­u­la­tors to sell its schiz­o­phre­nia drug Perseris — a re­lief, no doubt, con­sid­er­ing the com­pa­ny’s on­go­ing ex­clu­siv­i­ty war over its sta­ple drug Sub­ox­one.

This new­ly ap­proved med­i­cine, which used to be called RBP-7000, is a long-act­ing in­jectable de­liv­ered un­der the skin once per month. The drug con­tains risperi­done, a go-to treat­ment for schiz­o­phre­nia that’s al­ready FDA ap­proved. But In­di­v­ior’s ver­sion us­es an ex­tend­ed re­lease de­liv­ery sys­tem to form a de­pot that pro­vides sus­tained lev­els of the drug over the course of the month. The hope, In­di­v­ior says, is to help boost pa­tients’ ad­her­ence to tak­ing the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER